New drug combination for recurrent ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug (HS-20089) combined with another drug (bevacizumab) for women whose ovarian cancer has returned after responding to platinum-based chemotherapy. The goal is to see if this combination helps control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- Your ovarian cancer came back more than 6 months after finishing platinum-based chemotherapy (called 'platinum-sensitive').
- You are able to take care of yourself and are up and about (ECOG performance status 0 or 1).
- You can provide a sample of your tumor tissue (either fresh or from a previous biopsy).
- You have not had certain prior cancer treatments, including a class of drugs called topoisomerase I inhibitors (like irinotecan or topotecan), or antibody-drug conjugates (ADCs).
- You are willing to use effective birth control (if you could become pregnant) and are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
This trial tests a new drug, HS-20089, for people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hear when a new Platinum-sensitive Recurrent Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.